Cécile Chartier

Director/Board Member at CELLECTIS S.A.

Health Technology

Technology Services

Consumer Services

Profile

Cécile Chartier is currently working as a Director at Cellectis SA and as the Chief Scientific Officer at NextVivo, Inc. She holds a doctorate degree from Universite Louis Pasteur Strasbourg I.

Cécile Chartier active positions

Companies	Position	Start
CELLECTIS S.A.	Director/Board Member	2023-06-26
NextVivo, Inc. NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation.	Chief Tech/Sci/R&D Officer	-

All active positions of Cécile Chartier

Training of Cécile Chartier

Universite Louis Pasteur Strasbourg I

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Cécile Chartier's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
CELLECTIS S.A.	Health Technology

Private companies	1
NextVivo, Inc. NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation.	Technology Services